Screening Novel Agent Combinations to Expedite CTCL Therapeutic Development
- PMID: 32534802
- DOI: 10.1016/j.jid.2020.05.097
Screening Novel Agent Combinations to Expedite CTCL Therapeutic Development
Similar articles
-
Haematological cancer: Resiquimod—a topical CTCL therapy.Nat Rev Clin Oncol. 2015 Oct;12(10):563. doi: 10.1038/nrclinonc.2015.142. Epub 2015 Aug 25. Nat Rev Clin Oncol. 2015. PMID: 26305037 No abstract available.
-
Bexarotene monotherapy for epidermotropic CD8+ CTCL.Dermatol Clin. 2008 Jan;26 Suppl 1:45-7. Dermatol Clin. 2008. PMID: 18405187 No abstract available.
-
New drugs in cutaneous T-cell lymphomas.Curr Opin Oncol. 2016 Sep;28(5):384-9. doi: 10.1097/CCO.0000000000000311. Curr Opin Oncol. 2016. PMID: 27390044 Review.
-
Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.Hematology. 2015 Oct;20(9):538-42. doi: 10.1179/1607845415Y.0000000002. Epub 2015 Jan 16. Hematology. 2015. PMID: 25592781 Clinical Trial.
-
HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.Future Med Chem. 2012 Mar;4(4):471-86. doi: 10.4155/fmc.12.6. Future Med Chem. 2012. PMID: 22416775 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical